Hydroxychloroquine Market Size, Industry Growth Prospects & Trends Analysis
Hydroxychloroquine Market |
Hydroxychloroquine is a
medication that is commonly used to prevent and treat malaria. The
pharmacokinetics of hydroxychloroquine are comparable to chloroquine. It is
quickly absorbed in the gastrointestinal tract and excreted by the kidneys. In
addition, hydroxychloroquine is used to treat rheumatoid arthritis, lupus erythematosus,
and delayed skin lesions purpura.
India is a significant
producer of hydroxychloroquine. The potential of this drug in treating COVID-19
compelled India to impose a ban on its export, resulting in tensions in
US–India diplomatic relations. At the moment, approximately 80 countries around
the world rely on Indian medicine. Hydroxychloroquine (Plaquenil) is a disease-modifying
anti-rheumatic medication. Individuals' high prevalence of joint pain and
long-term disability has fueled demand for hydroxychloroquine drugs. Plaquenil
has received a lot of attention for its ability to effectively reduce arthritis
pain and swelling.
The hydroxychloroquine
market drugs are being driven by an alarmingly high number of childhood
arthritis cases and other autoimmune diseases. However, the drug has the
potential to cause severe hypoglycemia. Diabetic patients are thus advised to
monitor their blood sugar levels on a regular basis. However, in areas where
chloroquine resistance has been reported, the hydroxychloroquine market has been
found to be ineffective against malaria. As a result, pharmaceutical companies
are advocating for a better understanding of the impact of low-quality drugs on
malaria control.
Hydroxychloroquine drugs are the gold
standard for malaria treatment. However, in many cases, healthcare
professionals have encountered drug resistance in patients, which is likely to
have an impact on the market for hydroxychloroquine drugs. As a result, hydroxychloroquine
drug manufacturers are taking cues from the WorldWide Antimalarial Resistance
Network (WWARN), which facilitates study groups that generate a pooled analysis
of the efficacy and safety of hydroxychloroquine drugs.
Cadila Healthcare Ltd., Hikma Pharmaceuticals
PLC, Ipca Laboratories Ltd., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A.,
Taj Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Torrent
Pharmaceuticals Ltd., and Zydus Cadila are the major players in the
hydroxychloroquine industry. The players are constantly focusing on R&D to
determine the impact of various coatings on coronavirus.
Comments
Post a Comment